文献速递姑息放疗与转移瘤消化道肿瘤放疗

局限性黏膜相关淋巴组织淋巴瘤单纯放疗的前瞻性疗效与毒性试验

A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-12-10

这项前瞻性试验纳入75例局限性MALT淋巴瘤患者,接受累及野放疗24–39.6 Gy,中位随访9.8年,10年无复发生存率83%、无进展生存率71%、总生存率86%,复发均可成功挽救,急性毒性多为1–2级,证实单纯放疗长期疗效优异且毒性可接受。

要点

  • 局限性MALT淋巴瘤单纯放疗10年无复发生存率83%,中位无进展生存17.5年。
  • 全部患者达完全缓解,中位起效3个月;复发多位于放疗野外。
  • 急性毒性92%为1–2级,仅1例3级;晚期毒性30%,仅1例3级。

核心结论

  • 单纯放疗对局限性MALT淋巴瘤可获优异长期无复发生存,毒性可接受。
  • 当前方向为放疗降阶梯以进一步减少治疗相关并发症。

研究设计与样本

  • 前瞻性单臂试验,2000–2012年入组75例局限性MALT淋巴瘤患者,73例接受方案规定放疗。
  • 放疗为累及野照射,剂量24–39.6 Gy,主要终点为无复发生存(RFS)。

主要发现

  • 中位随访9.8年,全部患者达完全缓解,中位达完全缓解时间3个月。
  • 10年RFS率83%(95%CI 74%–93%),10年PFS率71%(95%CI 60%–84%),10年OS率86%(95%CI 77%–96%)。
  • 全部复发均成功挽救,无患者死于MALT淋巴瘤。

关键数值与推荐

  • 放疗剂量24–39.6 Gy,累及野照射。
  • 胃MALT 34例中13例初诊幽门螺杆菌阳性并接受1–3疗程三联抗生素,入组前内镜证实持续MALT而无幽门螺杆菌。

临床怎么用

  • 局限性MALT淋巴瘤可采用单纯累及野放疗,剂量24–39.6 Gy。
  • 放疗后需关注野外复发,复发仍可有效挽救。
  • 胃MALT患者放疗前应确认幽门螺杆菌状态及内镜持续病变。

局限性

  • 单臂前瞻性试验,无随机对照组。
  • 样本量75例,部分亚组病例数较少。
  • 原文未报告具体毒性类型及放疗技术细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report the long-term results of a prospective trial conducted to determine the efficacy and safety of radiation therapy (RT) alone in treating localized mucosa-associated lymphoid tissue (MALT) lymphoma. METHODS AND MATERIALS: Patients with localized MALT lymphoma were eligible and treated with involved field RT to doses of 24 to 39.6 Gy. Relapse-free survival (RFS) was the primary endpoint. Kaplan-Meier analysis was used to estimate RFS, progression-free survival (PFS), and overall survival (OS) defined from time of study entry. Preplanned subgroup analyses were performed based on site of involvement. RESULTS: From 2000 to 2012, 75 patients were accrued; 73 received protocol-specified RT. Median follow-up was 9.8 years. Thirty-four patients had gastric MALT, 17 orbital, 13 head and neck nonorbit, 4 skin, and 5 disease of other sites. Thirteen of 34 patients with gastric MALT were Helicobacter pylori positive at the time of initial diagnosis and underwent 1 to 3 courses of triple antibiotic therapy. All gastric MALT patients had documented persistent MALT without H. pylori on endoscopy before enrollment in the study. All patients achieved a complete response with a median time of 3 months. Eleven patients (15%) had disease relapse, 9 of which were at sites outside the RT field with median time to progression of 38.3 months. Median PFS was 17.5 years, and median RFS and OS were not reached. The 10-year relapse-free rate was 83% (95% confidence interval [CI], 74%-93%). The 10-year PFS rate was 71% (95% CI, 60%-84%). The 10-year OS rate was 86% (95% CI, 77%-96%). RFS, PFS, and OS did not differ by disease site (P = .17, .43, and .50, respectively). All relapses were successfully salvaged. One patient developed metastatic gastric adenocarcinoma and was found to also have recurrent MALT on biopsy. Otherwise, all relapsed patients were alive without evidence of disease at last follow-up, and no patient died of MALT lymphoma. Sixty-seven patients (92%) experienced acute toxicity during radiation, all of which were grade 1 and 2, with only 1 grade 3 toxicity. Twenty-two patients (30%) experienced late toxicity, with only 1 grade 3 toxicity. CONCLUSIONS: This prospective study confirms that RT for MALT lymphoma provides excellent long-term RFS with acceptable rates of toxicity. Current efforts are focused on RT de-escalation in an effort to further avoid treatment-related morbidity. CLINICALTRIALS.GOV: NCT04465162.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Fang P, Gunther JR, Pinnix CC, et al. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys. 2020. PMID: 33309978. doi:10.1016/j.ijrobp.2020.11.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。